ESLA Q1 2024 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$469,530

Net Income

-$469,530

EPS (Diluted)

$-0.01

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$9M

Total Liabilities

$138,491

Stockholders' Equity

$8M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$469,530	-$149,650	-213.8%
Net Income	-$469,530	-$63,325	-641.5%